As expected, vehicle‐treated 5xFAD mice displayed proteomic signatures consistent with AD progression, including upregulation of App, apoE, Gfap, and C1qa, along with enrichment of immune response, proteostasis, lipid metabolism, apoptosis, and APP metabolism pathways. This evidence concerns the gene GFAP and Alzheimer disease.